Weak Statutory Earnings May Not Tell The Whole Story For Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093)

Despite Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s (SZSE:301093) recent earnings report having lackluster headline numbers, the market responded positively. While shareholders may be willing to overlook soft profit numbers, we believe that they should also be taking into account some other factors which may be cause for concern.

View our latest analysis for Jiangsu Hualan New Pharmaceutical MaterialLtd

How Do Unusual Items Influence Profit?

To properly understand Jiangsu Hualan New Pharmaceutical MaterialLtd's profit results, we need to consider the CN¥14m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Jiangsu Hualan New Pharmaceutical MaterialLtd's positive unusual items were quite significant relative to its profit in the year to June 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Jiangsu Hualan New Pharmaceutical MaterialLtd's Profit Performance

As we discussed above, we think the significant positive unusual item makes Jiangsu Hualan New Pharmaceutical MaterialLtd's earnings a poor guide to its underlying profitability. For this reason, we think that Jiangsu Hualan New Pharmaceutical MaterialLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that its earnings per share increased slightly in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Jiangsu Hualan New Pharmaceutical MaterialLtd.

Today we've zoomed in on a single data point to better understand the nature of Jiangsu Hualan New Pharmaceutical MaterialLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.